Acromegaly Pipeline Insights and Clinical Trials Report 2023

DelveInsight's, "Acromegaly Pipeline Insight 2023" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Acromegaly pipeline landscape. It covers the Acromegaly pipeline drug profiles, including Acromegaly clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Acromegaly Pipeline Report

• Over 15+ Acromegaly companies are evaluating 15+ Acromegaly pipeline therapies in various stages of development, and their anticipated acceptance in the Acromegaly market would significantly increase market revenue.
• The leading Acromegaly Companies includes Ionis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus, Ono Pharmaceutical, Aquestive Therapeutics, Strongbridge Biopharma, Italfarmaco, Ipsen, Antisense Therapeutics, Dauntless Pharmaceuticals, TTY Biopharm, Peptron, DexTech Medical AB, Rani Therapeutics, OPKO Health, Inc., Amolyt Pharma, Foresee Pharmaceuticals, ADVANZ PHARMA, and others.
• Promising Acromegaly Pipeline Therapies includes octreotide FluidCrystal® injection depot, IONIS-GHR-LRx, SRL, Paltusotine, CAM2029 (octreotide subcutaneous depot), and others.
• The Acromegaly companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The Acromegaly pipeline therapies under development are focused on novel approaches to treat/improve Acromegaly.

Request a sample and discover the recent breakthroughs happening in the Acromegaly pipeline landscape @ Acromegaly Pipeline Outlook Report- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acromegaly Overview
Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. In adults, too much of this hormone causes bones, cartilage, body organs, and other tissues to increase in size. Common changes in appearance include enlarged or swollen nose, ears, hands, and feet. Acromegaly is most often diagnosed in middle-aged adults, but symptoms can appear at any age.

Acromegaly Emerging Drugs Profile

• IONIS-GHR-LRX: Ionis Pharmaceuticals
IONIS-GHR-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of the growth hormone receptor (GHr) to decrease the circulating level of insulin-like growth factor-1 (IGF-1). IGF-1 is a hormone primarily produced in the liver that plays an important role in childhood growth and has anabolic effects in adults. Several different diseases result from abnormally low or high levels of IGF-1, or an inappropriate response to this hormone. When produced in excess, IGF-1 results in acromegaly, a chronic, slowly progressing and life-threatening disease. Currently, it is in Phase II stage of development to treat Acromegaly.

• Paltusotine: Crinetics Pharmaceuticals
Paltusotine (formerly CRN00808) is an orally available nonpeptide biased agonist that is designed to be highly selective for the somatostatin type 2 receptor. It was designed by the Crinetics discovery team to provide a once daily oral option for patients with acromegaly and neuroendocrine tumors that are currently treated by injected therapies that sell approximately $3.1 billion annually. Non-clinical chronic toxicology studies are complete and no dose limiting toxicity was identified at the maximum feasible doses in rats and dogs. Crinetics previously completed a Phase 1 trial that showed potent suppression of the growth hormone (GH) axis in healthy volunteers, which provided clinical proof-of-concept. In addition, the molecule's observed plasma half-life of approximately 2 days suggested the potential for paltusotine for once daily oral administration. A subsequent Phase 1 trial showed that paltusotine was 70% orally bioavailable. Paltusotine is an investigational drug currently undergoing two Phase 2 clinical trials for the treatment of acromegaly, the ACROBAT Edge and Evolve trials. Paltusotine has been discovered, characterized, and developed by Crinetics and U.S. patents have been issued covering paltusotine to 2037. Currently, it is in Phase III stage of development to treat Acromegaly.

Find out more about the Acromegaly Diagnosis and Treatment of patients @ Acromegaly Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acromegaly Key Companies and Pipeline Therapies
• octreotide FluidCrystal® injection depot: Ionis Pharmaceuticals
• IONIS-GHR-LRx: Crinetics Pharmaceuticals
• SRL: Camurus
• Paltusotine: Ono Pharmaceutical
• CAM2029 (octreotide subcutaneous depot): Aquestive Therapeutics

Acromegaly Pipeline Therapeutics Assessment
Phases
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Discover more about the list of Acromegaly FDA-approved drugs for Acromegaly @ Acromegaly Treatment Landscape- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acromegaly Pipeline Report
• Coverage- Global
• Acromegaly Companies- Ionis Pharmaceuticals (NYSE: IONS), Crinetics Pharmaceuticals (NYSE: CRNX), Camurus (NYSE: CAMX), Ono Pharmaceutical (NYSE: OPHLF), Aquestive Therapeutics (NYSE: AQST), Strongbridge Biopharma (NYSE: SBBP), Italfarmaco, Ipsen, Antisense Therapeutics (NYSE: ATHJF), Dauntless Pharmaceuticals, TTY Biopharm, Peptron, DexTech Medical AB (NYSE: DEX), Rani Therapeutics (NYSE: RANI), OPKO Health Inc (NYSE: OPK)., Amolyt Pharma, Foresee Pharmaceuticals, ADVANZ PHARMA, and others.
• Acromegaly Pipeline Therapies- octreotide FluidCrystal® injection depot, IONIS-GHR-LRx, SRL, Paltusotine, CAM2029 (octreotide subcutaneous depot), and others
• Acromegaly Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type

Dive deep into rich insights for Acromegaly Emerging Therapies and Ongoing Clinical Trials; visit @ Acromegaly Emerging Therapies and Key Players- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Acromegaly: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Paltusotine: Crinetics Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. IONIS-GHR-LRX: Ionis Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. RaniPill: Rani Therapeutics
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. AZP-3800: Amolyt Pharma
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Acromegaly Key Companies
20. Acromegaly Key Products
21. Acromegaly- Unmet Needs
22. Acromegaly- Market Drivers and Barriers
23. Acromegaly- Future Perspectives and Conclusion
24. Acromegaly Analyst Views
25. Acromegaly Key Companies
26. Appendix

For further information on the Acromegaly Pipeline therapeutics, reach out to Acromegaly Future Perspectives and Unmet Needs- https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.